Latest Insider Transactions at C4 Therapeutics, Inc. (CCCC)
This section provides a real-time view of insider transactions for C4 Therapeutics, Inc. (CCCC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of C4 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of C4 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 13
2023
|
Stewart Fisher Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+20.24%
|
-
|
|
Feb 08
2023
|
Utpal Koppikar Director |
BUY
Open market or private purchase
|
Direct |
5,667
+50.0%
|
$28,335
$5.6 P/Share
|
|
Jan 30
2023
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-20.33%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Jolie Siegel Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+36.95%
|
-
|
|
Jan 30
2023
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-20.33%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Kelly Schick Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+36.95%
|
-
|
|
Jan 30
2023
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,319
-13.79%
|
$30,233
$7.78 P/Share
|
|
Jan 30
2023
|
Andrew Hirsch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+28.52%
|
-
|
|
Jan 30
2023
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,222
-19.1%
|
$8,554
$7.78 P/Share
|
|
Jan 30
2023
|
Scott N Boyle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+36.95%
|
-
|
|
Jan 30
2023
|
Lauren White Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-20.33%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Lauren White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+36.95%
|
-
|
|
Jan 30
2023
|
Adam Crystal Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-6.08%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+14.91%
|
-
|
|
Jan 30
2023
|
Stewart Fisher Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-1.67%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+4.6%
|
-
|
|
Jan 06
2023
|
Kenneth Carl Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
712
+0.37%
|
$2,136
$3.55 P/Share
|
|
Jan 03
2023
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,725
+24.78%
|
$10,350
$6.38 P/Share
|
|
Jan 03
2023
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,763
+40.58%
|
$10,578
$6.38 P/Share
|
|
Jan 03
2023
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,568
+1.63%
|
$9,408
$6.38 P/Share
|
|
Oct 03
2022
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
819
+50.0%
|
$6,552
$8.69 P/Share
|
|
Oct 03
2022
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,265
+26.49%
|
$10,120
$8.69 P/Share
|
|
Oct 03
2022
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,150
+1.22%
|
$9,200
$8.69 P/Share
|
|
Oct 03
2022
|
Kenneth Carl Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
712
+0.39%
|
$2,136
$3.55 P/Share
|
|
Jul 15
2022
|
Kenneth Carl Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,424
+0.78%
|
$4,272
$3.55 P/Share
|
|
Jul 01
2022
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,372
+37.93%
|
$10,976
$8.03 P/Share
|
|
Jul 01
2022
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,246
+1.37%
|
$9,968
$8.03 P/Share
|
|
May 25
2022
|
Andrew Hirsch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+35.71%
|
-
|
|
May 25
2022
|
Scott N Boyle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
May 25
2022
|
Lauren White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
May 25
2022
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+4.75%
|
-
|
|
May 25
2022
|
Kelly Schick Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
May 25
2022
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+16.67%
|
-
|
|
May 25
2022
|
Jolie Siegel Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
Apr 12
2022
|
Andrew Hirsch President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.4 P/Share
|
|
Apr 12
2022
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,084
+15.59%
|
$112,336
$4.35 P/Share
|
|
Apr 04
2022
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
341
+0.38%
|
$8,866
$26.46 P/Share
|
|
Apr 04
2022
|
Alain J Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+29.48%
|
$10,088
$26.46 P/Share
|
|
Apr 04
2022
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
379
+30.27%
|
$9,854
$26.46 P/Share
|
|
Jan 26
2022
|
Kenneth Carl Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,137
+1.21%
|
$6,411
$3.55 P/Share
|
|
Jan 04
2022
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
278
+0.32%
|
$8,618
$31.58 P/Share
|
|
Jan 04
2022
|
Alain J Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
318
+37.06%
|
$9,858
$31.58 P/Share
|
|
Jan 04
2022
|
Marc A Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
657
+37.01%
|
$20,367
$31.58 P/Share
|
|
Jan 04
2022
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
199
+28.72%
|
$6,169
$31.58 P/Share
|
|
Jan 04
2022
|
Malcolm Salter Director |
BUY
Grant, award, or other acquisition
|
Direct |
428
+3.62%
|
$13,268
$31.58 P/Share
|
|
Jan 04
2022
|
Adam Crystal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-26.53%
|
$480,000
$32.13 P/Share
|
|
Jan 04
2022
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+33.33%
|
$90,000
$6.49 P/Share
|
|
Dec 22
2021
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+25.0%
|
$30,000
$6.49 P/Share
|
|
Dec 17
2021
|
Malcolm Salter Director |
SELL
Open market or private sale
|
Direct |
755
-6.45%
|
$22,650
$30.25 P/Share
|
|
Dec 08
2021
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,562
+12.95%
|
$61,686
$3.6 P/Share
|